# GRI Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/GRI Bio, Inc.). ## Overview GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory, fibrotic, and autoimmune diseases driven by dysregulated immune responses. The company has no approved products yet and is focused on advancing product candidates such as GRI-0621 and GRI-0803 through preclinical and clinical development toward eventual commercialization. ## Products & services • GRI-0621 clinical-stage product candidate • GRI-0803 clinical-stage product candidate • Preclinical discovery of immune-modulating therapies • Clinical development for inflammatory, fibrotic and autoimmune disorders • Future commercialization of approved therapies - **Clinical-stage product candidates** (0%) — Drug candidates in preclinical and clinical development, including GRI-0621 and GRI-0803. - **Research and development programs** (100%) — Discovery and development work aimed at immune-response targets for inflammatory and autoimmune disease. - **Future commercial therapies** (0%) — Potential marketed products if candidates receive regulatory approval and are launched. - GRI-0621 clinical-stage product candidate - GRI-0803 clinical-stage product candidate - Preclinical discovery of immune-modulating therapies - Clinical development for inflammatory, fibrotic and autoimmune disorders - Future commercialization of approved therapies ## Customers GRI Bio does not yet sell commercial products, so its near-term 'customers' are primarily clinical trial participants, investigators, CROs, and regulatory agencies involved in development. If approved, the eventual buyers would be physicians, hospitals, and third-party payors treating patients with inflammatory, fibrotic, and autoimmune disorders. - **Clinical development partners** (primary) — CROs, investigators, and trial sites that execute studies and generate data needed for regulatory advancement. - **Regulatory agencies** (primary) — FDA and other regulators that review safety, efficacy, and manufacturing data before approval. - **Physicians and specialists** (secondary) — Potential future prescribers in immunology, pulmonology, hepatology, and related specialties. - **Third-party payors** (secondary) — Commercial insurers and government programs that would influence adoption and reimbursement after approval. - **Patients with immune-mediated disease** (secondary) — End users of any approved therapy for inflammatory, fibrotic, or autoimmune disorders. - Clinical trial sites and CROs supporting development work - Regulators reviewing INDs and marketing applications - Physicians treating inflammatory and autoimmune diseases - Hospitals and specialty clinics that may prescribe approved drugs - Third-party payors that determine reimbursement access ## Geography GRI Bio is headquartered in La Jolla, California and operates as a U.S.-based development-stage biotech company. The business is currently centered on U.S. research, clinical, regulatory, and financing activities, with future commercial geography dependent on where approvals are obtained and where partners or patients are located. - Headquartered in La Jolla, California - U.S.-based clinical development and corporate operations - No disclosed country revenue mix because there is no product revenue - Future geographic exposure depends on trial sites and approval markets - Potential commercialization could expand beyond the U.S. ## Strategy The company’s strategy is to advance GRI-0621, GRI-0803, and future candidates through clinical development, while building the data package needed for regulatory approval. It also expects to raise capital and may seek collaborations or partnerships to fund development and reduce the burden of late-stage trials and commercialization. - **Advance lead clinical programs** (short-term) — The company has no approved products, so value creation depends on generating human efficacy and safety data. - **Secure additional funding** (short-term) — Management disclosed substantial doubt about going concern and expects continued operating losses. - **Build regulatory and manufacturing readiness** (medium-term) — Clinical-stage biotech must demonstrate quality, safety, and manufacturability before approval. - Advance GRI-0621 through clinical development - Progress GRI-0803 and other immune-targeted candidates - Use clinical data to support regulatory submissions - Seek external financing to fund development and operations - Consider strategic partnerships or collaborations ## Risks GRI Bio faces the core risks of a clinical-stage biotech: development failure, regulatory setbacks, and the need for repeated financing before any product revenue exists. Its business is also exposed to third-party dependence, competition from better-capitalized drug developers, cybersecurity risk, and healthcare reimbursement and compliance constraints if products are eventually approved. - **Clinical development failure** [critical] — GRI-0621, GRI-0803, and other candidates must still prove safety and efficacy in trials. - **Going concern / financing risk** [critical] — The company expects continued losses and disclosed substantial doubt about its ability to continue as a going concern. - **Regulatory approval risk** [high] — Drug candidates require IND clearance, clinical success, and marketing approval before commercialization. - **Competition from larger biopharma companies** [high] — Competitors may have greater capital, broader pipelines, and faster development capabilities. - **Cybersecurity and third-party operational risk** [medium] — The company relies on CROs, clinical sites, and contractors that process sensitive data and run trials. - No approved products, so success depends on clinical trial outcomes - Substantial doubt about going concern and ongoing financing needs - Competition from larger biotech and pharma companies with more resources - Third-party CRO, site, and supply-chain dependence can delay studies - Cybersecurity incidents could disrupt sensitive research data and operations - Future commercialization depends on reimbursement and market acceptance ## Accounting The most important accounting issues are R&D accruals, stock-based compensation, and lease accounting, because the company’s expenses are driven by outsourced studies, personnel, and office infrastructure rather than product sales. As a pre-revenue biotech, estimates around accrued CRO costs and clinical progress can materially affect quarterly operating results, while stock-based compensation and financing-related issuance costs can also distort comparability. - **Accrued research and development costs** — Can shift quarterly R&D expense and liabilities materially - **Stock-based compensation** — Affects operating loss and comparability across periods - **Lease accounting** — Impacts balance sheet leverage and occupancy expense timing - **Going concern assessment** — Important for interpreting financing risk and disclosure quality - R&D accruals depend on estimated CRO and study progress - Stock-based compensation affects operating expense and loss metrics - Operating lease accounting affects balance sheet liabilities and expense timing - No product revenue yet, so expense recognition drives reported results - Going-concern disclosures reflect liquidity assumptions and financing estimates --- *Last updated: 2026-04-28T20:10:42.257394+00:00*